Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Martindale Pharma has extended its agreement with AAH Pharmaceuticals (AAH) for exclusive distribution of its products to hospitals in England.
Subscribe to our email newsletter
It also announces it has been awarded over 20 products in response to a tender from the Department of Health for a new supply of medicines to maintain the Essential Medicines Buffer Stockpile over the next four years.
AAH will continue as supplier of Martindale Pharma’s products to NHS and private hospitals in England for a further three years.
Martindale Pharma will continue to use AAH for distribution of its hospital products in Scotland alongside TPS, and Northern Ireland alongside United Drug Sangers. Commercial terms were not disclosed.
Martindale Pharma CEO Michael Harris said: "We are delighted to have extended this partnership with AAH. As a major supplier of essential medicines to NHS and private hospitals, Martindale Pharma is committed to improving product supply and customer service to our hospital customers.
"We were impressed with AAH’s partnership approach to working with us and believe that this new three year agreement will continue to improve our supply chain."
Martindale Pharma also announces it has been awarded over 20 products from the Department of Health to provide important medicines to maintain the Essential Medicines Buffer Stockpile. The purpose of the Stockpile is to have essential medicines routinely used in the NHS, available for release into the UK supply chain in the event of pandemic or other health emergency.
The products which Martindale Pharma will supply includes emergency care medicines in pre-filled syringes and ampoules, as well as important treatments for opioid dependency. The contract runs for four years, and applies to drug stocks for England, Scotland, Wales and Northern Ireland. The value of the products Martindale Pharma will provide over that period is approximately £3.6m.
Michael Harris added: "We are very pleased to be awarded the majority of products that we tendered for. We believe that this illustrates and reinforces our position as a strategic partner to the NHS and the Department of Health and as a trusted UK supplier of essential medicines."